Drug Profile
Research programme: aggrecanase inhibitors - Rottapharm Biotech
Alternative Names: CR 4144/CR 4152; CR 4153; CR 4167; CR 5259; CRB 0017Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Rottapharm Madaus
- Developer Rottapharm Biotech
- Class Small molecules
- Mechanism of Action ADAMTS5 protein inhibitors; Aggrecanase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis in Italy
- 20 Feb 2015 Summit Corporation is now called Summit Therapeuitcs
- 10 Oct 2014 Rottapharm Madaus has been acquired by Meda